Received Jul 31, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | P2443 | — |
administering an early second dose of Twinrix (21 days after the first dose); This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too short in a female patient who received HAB (Twinrix) (batch number P2443, expiry date 18-SEP-2027) for prophylaxis. Concomitant products included Hepatitis a vaccine inact, Hepatitis b vaccine rHBsAg (yeast) (Twinrix). On 23-JUL-2025, the patient received the 2nd dose of Twinrix. On 23-JUL-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too short (Verbatim: administering an early second dose of Twinrix (21 days after the first dose)). The outcome of the drug dose administration interval too short was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 24-JUL-2025 The reporter wanted to know how to proceed after administering an early second dose of Twinrix (21 days after the first dose) to a patient that was getting vaccinated for immigration matters. The patient received 2nd dose of Twinrix earlier than recommended interval, which led to shortening of vaccination schedule.